Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03734588 · ClinicalTrials.gov registry record · Phase 1
Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors
A Phase 1 study of Genetic Diseases, Inborn and Blood Coagulation Disorder, sponsored by Spark Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 11
- Study locations
NCT03734588: Completed Phase 1 study of Genetic Diseases, Inborn and Blood Coagulation Disorder, sponsored by Spark Therapeutics.
NCT03734588 is a Phase 1 study of Genetic Diseases, Inborn and Blood Coagulation Disorder that has completed, run by Spark Therapeutics. The registered enrollment target is 4 participants, below the 188-participant average among 5 other Genetic Diseases, Inborn trials with a reported enrollment target (98% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03734588, a Phase 1 study of Genetic Diseases, Inborn and Blood Coagulation Disorder, has completed, sponsored by Spark Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 11
- Study locations
Study Summary
SPK-8016 is in development for the treatment of patients with inhibitors to FVIII. This Phase 1/2, open-label, non-randomized, dose-finding study to evaluate the safety, efficacy, and tolerability of SPK-8016 in adult males with severe hemophilia A and no measurable inhibitor against FVIII.
Primary Outcome
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this def
Conditions Studied
Interventions
- GENETIC SPK-8016
Study Locations (11)
Pennsylvania
- Penn State Health - Hershey
- Children's Hospital of Philadelphia - Philadelphia
- Jefferson University Hospitals - Philadelphia
- Hemophilia Center of Western Pennsylvania - Pittsburgh
California
- Orthopaedic Institute for Children - Los Angeles
Illinois
- Illinois Bleeding and Clotting Disorders Institute - Peoria
Michigan
- University of Michigan - Ann Arbor
Mississippi
- Mississippi Center for Advanced Medicine - Madison
New York
- Weill Cornell Medicine - New York
Oregon
- Oregon Health & Science University - Portland
Virginia
- Virginia Commonwealth University School of Medicine - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-01-30 |
| Est. Completion | 2023-01-19 |
| Phase | Phase 1 |
What the finished NCT03734588 record still lists
NCT03734588 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 188-participant average among 5 other Genetic Diseases, Inborn trials with a reported enrollment target (98% lower).
The record links to 10 conditions, with Genetic Diseases, Inborn appearing as the primary indexed condition, and to 1 intervention - of which SPK-8016 is the first listed.
NCT03734588 lists 11 locations in 8 states (Pennsylvania, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT03734588 about?
NCT03734588 is a clinical study titled "Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors". SPK-8016 is in development for the treatment of patients with inhibitors to FVIII. This Phase 1/2, open-label, non-randomized, dose-finding study to evaluate the safety, efficacy, and tolerability of SPK-8016 in adult males with severe hemophilia A and no measurable inhibitor against FVIII.
What is the current status of trial NCT03734588?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2019-01-30. Estimated completion is 2023-01-19.
What conditions does trial NCT03734588 study?
This clinical trial studies the following conditions: Genetic Diseases, Inborn, Blood Coagulation Disorder, Genetic Diseases, X-Linked, Blood Coagulation Disorders, Inherited, Factor VIII (FVIII).
What interventions are being tested in trial NCT03734588?
The interventions under investigation include: SPK-8016 (GENETIC).
Who is sponsoring clinical trial NCT03734588?
This trial is sponsored by Spark Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03734588 being conducted?
This trial has 11 study locations across California, Illinois, Michigan, Mississippi, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Diseases, Inborn
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RECRUITING · Phase 3
-
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
ACTIVE NOT RECRUITING · Phase 3
-
NYCKidSeq: Incorporating Genomics Into Clinical Care of Diverse NYC Children
COMPLETED · NA
-
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI